Angelman
57 programs · 55 companies
Programs
57
Companies
55
Trials
40
MOAs
39
CDK2iPCSK9iKIF18AiBCL-2iPD-L1iVEGFiWEE1iALKiPRMT5iEZH2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tirafotisoran | Phase 2 | CD38 | ||
| AZN-4015 | Preclinical | BCMA | ||
| TAK-1836 | Preclinical | EGFR | ||
| Tezecilimab | NDA/BLA | Tau | ||
| Motainavolisib | NDA/BLA | CD47 | ||
| BGN-8936 | Phase 1/2 | FXIa | ||
| Talatuximab | Preclinical | CD3 | ||
| Doxasotorasib | Phase 2/3 | CFTR | ||
| Teravorutinib | Phase 2 | JAK2 | ||
| MDG-611 | Approved | CGRP | ||
| SLR-5251 | Phase 3 | KRASG12D | ||
| Elraderotide | Phase 1/2 | Tau | ||
| UCB-6099 | Approved | SHP2 | ||
| IPN-129 | Approved | PD-L1 | ||
| ONC-2103 | Phase 1/2 | Tau | ||
| MD-IIT-285 | Phase 1 | SOS1 | ||
| CAM-IIT-818 | Phase 1/2 | JAK1 | ||
| MIR-7357 | Preclinical | USP1 | ||
| Darazasiran | Phase 3 | B7-H3 | ||
| ALG-2734 | Approved | Tau | ||
| Polazasiran | Phase 3 | KIF18A | ||
| INH-3643 | NDA/BLA | CD20 | ||
| Lisosertib | Phase 1 | Nectin-4 | ||
| Tezevorutinib | Approved | SHP2 | ||
| Mirimavacamten | Approved | EGFR | ||
| CRN-1592 | Phase 1/2 | CD20 | ||
| Semaglumide | Approved | SGLT2 | ||
| Sotovorutinib | Phase 2/3 | AuroraA | ||
| Cevitapinarof | Phase 2/3 | GIP-R | ||
| Nidacilimab | Preclinical | JAK1 | ||
| Zenoosocimab | Phase 1 | TNFα | ||
| Polalucimab | Phase 2 | CDK4/6 | ||
| Lisozasiran | Phase 1 | KRASG12C | ||
| ENC-8622 | Phase 3 | Tau | ||
| RYT-3886 | Phase 2/3 | Cl18.2 | ||
| MIM-1147 | Phase 2 | TYK2 | ||
| INT-3699 | Preclinical | GPRC5D | ||
| 456-7078 | Phase 1/2 | TIM-3 | ||
| Surazasiran | NDA/BLA | SGLT2 | ||
| 4D-4097 | Approved | Nectin-4 | ||
| Nirazumab | Phase 1 | BCL-2 | ||
| Tirazumab | Phase 2/3 | KIF18A | ||
| ITA-9145 | NDA/BLA | PI3Kα | ||
| EXA-3015 | Phase 1 | APOC3 | ||
| TWS-2496 | Phase 2/3 | CD47 | ||
| Daracilimab | Preclinical | TNFα | ||
| Liralemzoparlimab | Phase 3 | PI3Kα | ||
| BAY-3810 | Phase 2/3 | CD123 | ||
| SMM-5951 | Phase 2/3 | LAG-3 | ||
| Lisovorutinib | Phase 2/3 | BET | ||
| Voxanesiran | Phase 1 | CD47 | ||
| IRC-IIT-265 | Phase 1/2 | CD123 | ||
| ASA-IIT-599 | Phase 2/3 | B7-H3 | ||
| HOS-IIT-275 | Approved | PD-L1 | ||
| Sotoglumide | Phase 1/2 | ALK | ||
| AVT-8949 | Phase 3 | KRASG12C | ||
| Surarasimod | Phase 2 | BET |
Trials (40)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07109655 | Tezecilimab | NDA/BLA | Terminated |
| NCT03643580 | Tezecilimab | NDA/BLA | Recruiting |
| NCT04164054 | Motainavolisib | NDA/BLA | Active |
| NCT04692250 | BGN-8936 | Phase 1/2 | Active |
| NCT05976040 | Doxasotorasib | Phase 2/3 | Not yet recr... |
| NCT06095865 | Teravorutinib | Phase 2 | Recruiting |
| NCT05871565 | MDG-611 | Approved | Terminated |
| NCT03002214 | SLR-5251 | Phase 3 | Not yet recr... |
| NCT04650784 | Elraderotide | Phase 1/2 | Completed |
| NCT05614414 | IPN-129 | Approved | Recruiting |
| NCT03562532 | MD-IIT-285 | Phase 1 | Completed |
| NCT03176609 | CAM-IIT-818 | Phase 1/2 | Recruiting |
| NCT05269372 | ALG-2734 | Approved | Completed |
| NCT08254384 | Polazasiran | Phase 3 | Completed |
| NCT05096523 | Tezevorutinib | Approved | Completed |
| NCT03419908 | Mirimavacamten | Approved | Not yet recr... |
| NCT03667932 | Mirimavacamten | Approved | Not yet recr... |
| NCT04913753 | Mirimavacamten | Approved | Completed |
| NCT04447590 | CRN-1592 | Phase 1/2 | Active |
| NCT05034404 | CRN-1592 | Phase 1/2 | Active |